AKS 231
Alternative Names: AKS-231Latest Information Update: 28 Sep 2021
At a glance
- Originator Akston Biosciences
- Class Antihyperglycaemics; Insulins
- Mechanism of Action Insulin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral, Injection)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (Parenteral, Injection)
- 18 Aug 2017 Preclinical trials in Type-1 diabetes mellitus in USA (Parenteral) before August 2017 (Akston Biosciences pipeline, August 2017)